3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Venous Thromboembolism
15
Venous Thrombosis
11
Pulmonary Embolism
10
Neoplasms
9
Thrombosis
4
Thromboembolism
4
Pancreatic Neoplasms
4
Lung Neoplasms
4
Multiple Myeloma
3
Neoplasm Metastasis
2
Lymphoma
2
Hemorrhage
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Thrombophilia
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Obesity
1
Neoplasms, Plasma Cell
1
Interventions
Gemcitabine
60
Cisplatin
38
Oxaliplatin
30
Capecitabine
28
Fluorouracil
21
Leucovorin
19
pembrolizumab
11
Irinotecan
11
durvalumab
9
130-nm albumin-bound paclitaxel
9
Erlotinib Hydrochloride
8
Trastuzumab
7
Bevacizumab
7
Platinum
6
Magnetic Resonance Spectroscopy
6
Albumin-Bound Paclitaxel
6
1,2-diaminocyclohexaneplatinum II citrate
6
Taxes
5
Specimen Handling
5
Sorafenib
5
Radiotherapy
5
Carboplatin
5
Docetaxel
4
Biopsy
4
trifluridine tipiracil drug combination
3
dehydroftorafur
3
atezolizumab
3
Paclitaxel
3
Lapatinib
3
Interleukin-12 Subunit p35
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gallbladder Neoplasms
×
Dalteparin
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled